Compare Live Nation Entertainment, Inc. (LYV) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Neurocrine Biosciences Inc — how do they compare? Live Nation Entertainment, Inc. trades at $171.11 (market cap $39.80B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Live Nation Entertainment, Inc. is far larger — about 2.7× Neurocrine Biosciences Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LYV | NBIX | |
|---|---|---|
Market Cap | $39.80B | $14.60B |
Volume | 1,162,440 | 1,075,694 |
Sector | Media | Health |
52-Week High | $188.46 | $185.50 |
52-Week Low | $125.61 | $123.10 |
Typical Hold Time | 72 Days | 23 Days |
Enterprise Value | $42.01B | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation Entertainment (LYV) trades at $171.34, down 0.26% on the day, with a bullish technical signal and strong analyst support (87% buy ratings). The company reported mixed Q2 2026 earnings with a beat on EPS but faces valuation concerns with a P/E of 117.5 and negative ROE of -116.7%. Recent news highlights strong consumer demand for live events and strategic partnerships, though regulatory scrutiny and insider selling warrant attention.
The outlook remains positive given robust fan attendance and deferred revenue growth, but high valuation and execution risks in a seasonally heavy Q4 present challenges. Wall Street's $208 price target suggests 21% upside, positioning LYV as a growth play on experiential spending trends with balanced risk-reward dynamics.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
